Goldman Sachs Group set a €86.00 ($100.00) price objective on MorphoSys (ETR:MOR) in a research report released on Wednesday, September 26th. The brokerage currently has a neutral rating on the stock.
MOR has been the topic of several other reports. Independent Research set a €120.00 ($139.53) price objective on MorphoSys and gave the company a neutral rating in a research report on Tuesday, August 7th. Commerzbank set a €107.00 ($124.42) price objective on MorphoSys and gave the company a neutral rating in a research report on Wednesday, August 22nd. JPMorgan Chase & Co. set a €100.00 ($116.28) price objective on MorphoSys and gave the company a buy rating in a research report on Thursday, August 2nd. Deutsche Bank set a €120.00 ($139.53) price objective on MorphoSys and gave the company a neutral rating in a research report on Monday, July 30th. Finally, Royal Bank of Canada set a €62.00 ($72.09) price objective on MorphoSys and gave the company a sell rating in a research report on Thursday, July 19th. Two equities research analysts have rated the stock with a sell rating, five have given a hold rating and three have assigned a buy rating to the company’s stock. The company currently has a consensus rating of Hold and an average price target of €95.80 ($111.40).
MorphoSys stock traded up €1.10 ($1.28) during trading hours on Wednesday, hitting €81.45 ($94.71). 300,197 shares of the stock traded hands, compared to its average volume of 153,687. MorphoSys has a one year low of €49.63 ($57.71) and a one year high of €88.10 ($102.44).
MorphoSys AG, together with its subsidiaries, engages in the research, development, and optimization of therapeutic antibody drug candidates in partnership with pharmaceutical and biotechnology companies. The company, together with its pharmaceutical partners, develops a therapeutic pipeline of approximately 100 drugs for the treatment of cancer, Alzheimer's disease, infectious diseases, cardiovascular dysfunction, and inflammation.
Featured Article: Price to Earnings Ratio (PE) Basics
Receive News & Ratings for MorphoSys Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MorphoSys and related companies with MarketBeat.com's FREE daily email newsletter.